{"created":"2023-05-15T15:01:05.290171+00:00","id":82870,"links":{},"metadata":{"_buckets":{"deposit":"feca60fd-36cb-47a9-8409-0aab17864ea6"},"_deposit":{"created_by":1,"id":"82870","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"82870"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00082870","sets":["11"]},"author_link":["950939","950937","950938","950936"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"194","bibliographicPageStart":"191","bibliographicVolumeNumber":"59","bibliographic_titles":[{"bibliographic_title":"Geriatric Medicine（老年医学）"}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"バイオマーカーに求められる役割は、診断、経過の把握、予後や治療反応の予測など多岐にわたる。認知症の実臨床においては、治療可能な認知症の除外と大まかな背景病理に対応する状態を評価することが現状であり、具体的な背景病理の確認にはまだ限界がある。疾患修飾薬の開発ならびにこれを用いた先制治療においては、発症前を含む超早期診断と治療反応評価に寄与するバイオマーカーが重要となり、アミロイドPETは前者に、タウPETは前者および後者に寄与するものと期待される。Aβを標的とした診断・治療が現実のものとなりつつあるが、より簡便で低侵襲かつ安価なバイオマーカーの開発が期待される。","subitem_description_type":"Abstract"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"遠藤, 浩信"}],"nameIdentifiers":[{"nameIdentifier":"950936","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"島田, 斉"}],"nameIdentifiers":[{"nameIdentifier":"950937","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hironobu, Endo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"950938","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hitoshi, Shimada","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"950939","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"臨床に役立つQ&A 1. ADの早期診断におけるバイオマーカーの役割はどのようなことか","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"臨床に役立つQ&A 1. ADの早期診断におけるバイオマーカーの役割はどのようなことか"}]},"item_type_id":"10004","owner":"1","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-05-25"},"publish_date":"2021-05-25","publish_status":"0","recid":"82870","relation_version_is_last":true,"title":["臨床に役立つQ&A 1. ADの早期診断におけるバイオマーカーの役割はどのようなことか"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:08:58.005866+00:00"}